GleamWall
中文EN

MANE Veradermics, Inc

Pharmaceutical Preparations · NYSE · SEC CIK 1827635 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-11.7%
ROA-11.6%
ROIC (approx.)-13.2%
Asset turnover—

Leverage & solvency

Liabilities / assets1.3%
Debt / equity0.00x
Current ratio77.68x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.88x
Accruals ratio-1.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue———————
R&D expense$16.07M$18.61M$20.93M$18.19M$18.10M$14.33M$11.45M
SG&A expense$12.70M$10.95M$8.94M$4.82M$2.25M$1.74M$1.47M
Operating income-$28.78M-$29.55M-$29.86M-$23.01M-$20.35M-$16.07M-$12.91M
Pretax income-$21.00M-$23.50M-$27.23M-$21.85M-$20.10M-$15.64M-$12.40M
Income tax$0$0$0$0$0$0$0
Net income-$21.00M-$23.50M-$27.23M-$21.85M-$20.10M-$15.64M-$12.40M
EPS (basic)-0.50-0.58-1.32—-30.15-24.19-19.79
EPS (diluted)-0.50-0.58-1.32—-30.15-24.19-19.79
Weighted avg. shares (diluted)42.12M40.44M22.70M—748,485744,641736,933
Balance sheet
Cash & equivalents$132.16M$319.33M$168.41M$21.77M$5.66M$8.60M$32.44M
Short-term investments$666.19M$500.56M$222.38M$120.10M———
Current assets$805.78M$824.75M$397.07M$152.49M———
PP&E, net$386,000$41,000$21,000$22,000———
Total assets$807.22M$825.74M$397.36M$152.62M———
Current liabilities$10.37M$11.69M$6.72M$9.15M———
Total liabilities$10.74M$12.12M$6.72M$9.16M———
Shareholders' equity$796.47M$813.61M$390.64M-$121.01M-$96.01M-$76.07M-$60.67M
Shares outstanding42.19M41.78M37.34M749,760———
Cash flow statement
Operating cash flow-$22.95M-$14.49M-$21.17M-$23.63M-$19.01M-$15.64M-$13.32M
Capital expenditure$346,000$21,000$0$5,000$0$0$19,000
Free cash flow-$23.29M-$14.51M-$21.17M-$23.63M-$19.01M-$15.64M-$13.34M
Investing cash flow-$165.56M-$277.29M-$101.30M-$109.78M$15.00M-$8.33M-$15.75M
Financing cash flow$1.33M$442.70M$269.11M$149.51M$1.08M$129,000$8.42M
Stock-based compensation$4.09M$3.52M$5.26M$974,000$138,000$115,000$213,000

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.